Trial
NCT04971512
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Enanta Pharmaceuticals, Inc
Collaborators
—
Condition
Chronic Hepatitis B Virus Infection
Intervention
EDP-721
Why stopped
Due to adverse safety signals in Part 1 (HV)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-14